Shopping Cart 0
Cart Subtotal
AED 0

Biologics MGR 2017

Bundle Purchase

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 22020

Access to Printed Report; No Soft Copy
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : Printed Publication/ Book by Post

Hard Copy License
AED 22020

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 33030

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

CD-Rom
AED 22020

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 44040

Details

Biologics market covers biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnology methods and other cutting-edge technologies.

The global biologics market was estimated to be around $210 billion as of 2016. It made up around 20% of the overall pharmaceuticals market in 2016. The biologics was the second largest market, following the pharmaceutical drugs market in the global pharmaceutical market in 2016.

Treatment of complex diseases

Biologics provide effective treatment for many complex diseases such as Rheumatoid arthritis that have less treatment options. There has been significant advancement for the treatment of Rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of Rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan).

The Biologics Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global satellite and telecommunications resellers sector.

Reasons to Purchase

Outperform competitors using accurate up to date demand-side dynamics information.

Identify growth segments for investment.

Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.

Create regional and country strategies on the basis of local data and analysis.

Stay abreast of the latest customer and market research findings

Benchmark performance against key competitors.

Develop strategies based on likely future developments.

Utilize the relationships between key data sets for superior strategizing.

Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Gain a global perspective on the development of the market.

Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:

Where is the largest and fastest growing market for the biologics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical market, and compares it with other markets.

The market characteristics section of the report defines and explains the market.

The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down market into sub markets.

The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.

The biologics market section of the report gives context. It compares the biologics market with other segments of the pharmaceutical market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The biologics Indicators Comparison.

The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.

Scope

Markets Covered: Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines

Companies Mentioned: Johnson & Johnson, Pfizer Inc., Novartis AG, Abbvie, and Sanofi

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Biologics Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

READ MORE

Table Of Content

Scope

1. Biologics Market Characteristics;

2. Biologics Market Size And Growth;

2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;

3. Pestle Analysis;

3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;

4. Biologics Market Customer Information;

5. Biologics Market Segmentation;

5.1. Global Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 5.2. Global Biologics Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Biologics Market Trends And Strategies; 5.4 Global Biologics Market Compared With Similar Markets, 2016; 5.5 Global Biologics Market Compared With Similar Markets, 2012-2020, Historic and Forecast; 5.6 Biologics Market Compared With Similar Markets, 2016, By Region; 5.7 Biologics Market Compared With Similar Markets, 2016, By Country; 5.8 Therapeutic Proteins; 5.8.1. Market Characteristics; 5.8.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment; 5.8.3. Market Trends And Strategies; 5.9 Monoclonal Antibodies (MABS); 5.9.1. Market Characteristics; 5.9.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment; 5.9.3. Market Trends And Strategies; 5.10 Vaccines; 5.9.1. Market Characteristics; 5.10.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment; 5.10.3. Market Trends And Strategies;

6. Biologics Market Regional And Country Analysis;

6.1. Global Biologics Market, 2016, By Region; 6.2. Global Biologics Market, 2012-2020, Historic And Forecast, By Region; 6.3. Biologics Market, 2016, By Country; 6.4. Biologics Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Healthcare Market Segments, 2016, By Region; 6.6. Global Pharmaceuticals Market Segments, 2016, By Region; 6.7. Global Healthcare Market Segments, 2016, By Country; 6.8. Global Pharmaceuticals Market Segments, 2016, By Country;

7. Global Biologics Market Comparison With Macro Economic Factors;

7.1. Biologics Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Biologics Expenditure, Global;

8. Biologics Market Comparison With Macro Economic Factors Across Countries;

8.1. Biologics Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Biologics Expenditure, By Country;

9. Biologics Market Comparison With Industry Metrics;

9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Biologics Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Biologics Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Number Of Employees In Pharmaceutical Industry, 2016, By Country; 9.6. Global Biologics Market Revenue Versus Number Of Employees In Pharmaceutical Industry, 2016, By Country; 9.7. Global Average Spending On R&D/Product Development, 2016, By Country; 9.8. Global Biologics Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.9. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.10. Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.11. Global Generic & Branded Sales Proportion By Country (Volume), 2016, By Country; 9.12. Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2016, By Country; 9.13. Global Number Of Pharmacies, 2016, By Country; 9.14. Global Biologics Market Revenue Versus Number Of Pharmacies, 2016, By Country; 9.15. Global New Drug Approvals, 2016, By Country; 9.16. Global Biologics Market Revenue Versus New Drug Approvals, 2016, By Country; 9.17. Prevalent Cases Of Thalassemia, 2014, By Country; 9.18. Global Number Of General Practitioners 2016, By Country; 9.19. Global Biologics Market Revenue Versus Number Of General Practitioners, 2016, By Country;

10. Asia-Pacific Biologics Market;

10.1.1. Asia-Pacific Biologics Market Overview; 10.1.2. Asia-Pacific Biologics Historic Market, 2012-2016; 10.1.3. Asia-Pacific Biologics Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.2. Asia-Pacific Biologics Market: Country Analysis; 10.3. China Biologics Market; 10.3.1. China Biologics Market Overview; Average Salaries Of Pharmacists; 10.3.2. China Biologics Historic Market, 2012-2016; 10.3.3. China Biologics Forecast Market, 2016-2020; 10.3.4. China Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.3.5. China Biologics Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Biologics Expenditure, 2012-2020; 10.4. India Biologics Market; 10.4.1. India Biologics Market Overview; Average Salaries Of Pharmacists; 10.4.2. India Biologics Historic Market, 2012-2016; 10.4.3. India Biologics Forecast Market, 2016-2020; 10.4.4. India Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.4.5. India Biologics Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Biologics Expenditure, 2012-2020; 10.5. Japan Biologics Market; 10.5.1. Japan Biologics Market Overview; Average Salaries Of Pharmacists; 10.5.2. Japan Biologics Historic Market, 2012-2016; 10.5.3. Japan Biologics Forecast Market, 2016-2020; 10.5.4. Japan Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.5.5. Japan Biologics Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Biologics Expenditure, 2012-2020; 10.5.7. Japan Biologics Market Comparison With Industry Metrics; 10.5.7.1. Japan Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 10.5.7.2. Japan Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 10.6. Australia Biologics Market; 10.6.1. Australia Biologics Historic Market, 2012-2016; 10.6.2. Australia Biologics Forecast Market, 2016-2020; 10.6.3. Australia Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.6.4. Australia Biologics Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Biologics Expenditure, 2012-2020;

11. Western Europe Biologics Market;

11.1.1. Western Europe Biologics Market Overview; 11.1.2. Western Europe Biologics Historic Market, 2012-2016; 11.1.3. Western Europe Biologics Forecast Market, 2016-2020; 11.1.4. Western Europe Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.2. Western Europe Biologics Market: Country Analysis; 11.3. UK Biologics Market; 11.3.1. UK Biologics Market Overview; Average Salaries Of Pharmacists; 11.3.2. UK Biologics Historic Market, 2012-2016; 11.3.3. UK Biologics Forecast Market, 2016-2020; 11.3.4. UK Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.3.5. UK Biologics Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Biologics Expenditure, 2012-2020; 11.3.7. UK Biologics Market Comparison With Industry Metrics; 11.3.7.1 UK Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.3.7.2 UK Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.4. Germany Biologics Market; 11.4.1. Germany Biologics Historic Market, 2012-2016; 11.4.2. Germany Biologics Forecast Market, 2016-2020; 11.4.3. Germany Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.4.4 Germany Biologics Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Biologics Expenditure, 2012-2020; 11.4.6 Germany Biologics Market Comparison With Industry Metrics; 11.4.7.1 Germany Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.4.7.2 Germany Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.5 France Biologics Market; 11.5.1 France Biologics Historic Market, 2012-2016; 11.5.2 France Biologics Forecast Market, 2016-2020; 11.5.3 France Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.5.4 France Biologics Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Biologics Expenditure, 2012-2020; 11.5.6 France Biologics Market Comparison With Industry Metrics; 11.5.6.1 France Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.5.6.2 France Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.6. Italy Biologics Market; 11.6.1. Italy Biologics Historic Market, 2012-2016; 11.6.2. Italy Biologics Forecast Market, 2016-2020; 11.6.3. Italy Biologics Market, 2016, By Segment; Therapeutic Proteins; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.6.4. Italy Biologics Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Biologics Expenditure, 2012-2020; 11.6.6. Italy Biologics Market Comparison With Industry Metrics; 11.6.6.1 Italy Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.6.6.2 Italy Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.7. Spain Biologics Market; 11.7.1. Spain Biologics Historic Market, 2012-2016; 11.7.2. Spain Biologics Forecast Market, 2016-2020; 11.7.3. Spain Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.7.4. Spain Biologics Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Biologics Expenditure, 2012-2020; 11.7.6. Spain Biologics Market Comparison With Industry Metrics; 11.7.6.1 Spain Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.7.6.2 Spain Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016;

12. Eastern Europe Biologics Market;

12.1.1. Eastern Europe Biologics Market Overview; 12.1.2. Eastern Europe Biologics Historic Market, 2012-2016; 12.1.3. Eastern Europe Biologics Forecast Market, 2016-2020; 12.1.4 Eastern Europe Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 12.2. Eastern Europe Biologics Market: Country Analysis; 12.3. Russia Biologics Market; 12.3.1. Russia Biologics Historic Market, 2012-2016; 12.3.2. Russia Biologics Forecast Market, 2016-2020; 12.3.3. Russia Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 12.3.4. Russia Biologics Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Biologics Expenditure, 2012-2020;

13. North America Biologics Market;

13.1.1. North America Biologics Market Overview; 13.1.2. North America Biologics Historic Market, 2012-2016; 13.1.3. North America Biologics Forecast Market, 2016-2020; 13.1.4. North America Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 13.2. North America Biologics Market: Country Analysis; 13.3. USA Biologics Market; 13.3.1. USA Biologics Historic Market, 2012-2016; 13.3.2. USA Biologics Forecast Market, 2016-2020; 13.3.3 USA Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 13.3.4. USA Biologics Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Biologics Expenditure, 2012-2020; 13.3.6. USA Biologics Market Comparison With Industry Metrics; 13.3.6.1 USA Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 13.3.6.2 USA Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016;

14. South America Biologics Market;

14.1.1. South America Biologics Market Overview; 14.1.2. South America Biologics Historic Market, 2012-2016; 14.1.3. South America Biologics Forecast Market, 2016-2020; 14.1.4. South America Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 14.2. South America Biologics Market: Country Analysis; 14.3. Brazil Biologics Market; 14.3.1. Brazil Biologics Historic Market, 2012-2016; 14.3.2. Brazil Biologics Forecast Market, 2016-2020; 14.3.3. Brazil Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 14.3.4. Brazil Biologics Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Biologics Expenditure, 2012-2020;

15. Middle East Biologics Market;

15.1.1. Middle East Biologics Market Overview; 15.1.2. Middle East Biologics Historic Market, 2012-2016; 15.1.3. Middle East Biologics Forecast Market, 2016-2020; 15.1.4. Middle East Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines;

16.1.1. Africa Biologics Market Overview; 16.1.2. Africa Biologics Historic Market, 2012-2016; 16.1.3. Africa Biologics Forecast Market, 2016-2020; 16.1.4. Africa Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines;

17. Biologics Market Competitive Landscape;

17.1. Company Profiles; 17.2. Johnson & Johnson; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Pfizer Inc.; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Novartis Ag; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Abbvie; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Sanofi; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;

18. Key Mergers And Acquisitions In The Biologics Market;

19. Market Background: Pharmaceuticals Market;

19.1.1. Pharmaceutical Market Characteristics; 19.1.2. Pharmaceutical Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Trends And Strategies; 19.2. Pharmaceutical Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Market, 2016, By Region; 19.2.2. Global Pharmaceutical Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Market, 2016, By Country; 19.2.4. Pharmaceutical Market, 2012-2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceuticals Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceuticals Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceuticals Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Expenditure, Global; 19.4. Pharmaceutical Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Market;

20. Pharmaceuticals Industry Financial Margins;

21. Appendix;

21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer


List Of Figure

Table 1: Global Biologics Historic Market Growth

Table 2: Global Biologics Forecast Market Growth

Table 3: Biologics Market Segmentation

Table 4: Global Biologics Market, 2016, By Segment

Table 5: Global Biologics Market, 2012-2020, Historic And Forecast, By Segment

Table 6: Global Biologics Market Compared With Similar Markets, 2016

Table 7: Global Biologics Market Compared With Similar Markets, 2012-2020, Historic and Forecast

Table 8: Biologics Market Compared With Similar Markets, 2016, By Region

Table 9: Biologics Market Compared With Similar Markets, 2016, By Country

Table 10: Global Therapeutic Proteins Market, 2016, By Segment

Table 11: Global Monoclonal Antibodies (MABS) Market, 2016, By Segment

Table 12: Global Vaccines Market, 2016, By Segment

Table 13: Global Biologics Market, 2016, By Region

Table 14: Global Biologics Market, 2012-2020, Historic And Forecast, By Region

Table 15: Biologics Market, 2016, By Country

Table 16: Biologics Market, 2012-2020, Historic And Forecast, By Country

Table 17: Global Healthcare Market Segments, 2016, By Region

Table 18: Global Pharmaceuticals Market Segments, 2016, By Region

Table 19: Global Healthcare Market Segments, 2016, By Country

Table 20: Global Pharmaceuticals Market Segments, 2016, By Country;

Table 21: Biologics Market Size, Percentage Of GDP, Global

Table 22: Per Capita Average Biologics Expenditure, Global

Table 23: Biologics Market Comparison With Macro Economic Factors Across Countries

Table 24: Biologics Market Size, Percentage Of GDP, By Country

Table 25: Per Capita Average Biologics Expenditure, By Country

Table 26: Global Number Of Pharmacists, 2016, By Country

Table 27: Global Biologics Market Revenue Versus Number Of Pharmacists, 2016, By Country

Table 28: Global Number Of Pharma Enterprises, 2016, By Country

Table 29: Global Biologics Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Table 30: Global Number Of Employees In Pharmaceutical Industry, 2016, By Country

Table 31: Global Biologics Market Revenue Versus Number Of Employees In Pharmaceutical Industry, 2016, By Country

Table 32: Global Average Spending On R&D/Product Development, 2016, By Country

Table 33: Global Biologics Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Table 34: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 35: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 36: Global Generic & Branded Sales Proportion By Country (Volume), 2016, By Country

Table 37: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2016, By Country

Table 38: Global Number Of Pharmacies, 2016, By Country

Table 39: Global Biologics Market Revenue Versus Number Of Pharmacies, 2016, By Country

Table 40: Global New Drug Approvals, 2016, By Country

Table 41: Global Biologics Market Revenue Versus New Drug Approvals, 2016, By Country

Table 42: Prevalent Cases Of Thalassemia, 2014, By Country

Table 43: Global Number Of General Practitioners 2016, By Country

Table 44: Global Biologics Market Revenue Versus Number Of General Practitioners, 2016, By Country

Table 45: Asia-Pacific Biologics Historic Market, 2012-2016

Table 46: Asia-Pacific Biologics Forecast Market, 2016-2020

Table 47: Asia-Pacific Biologics Market, 2016, By Segment

Table 48: China Biologics Historic Market, 2012-2016

Table 49: China Biologics Forecast Market, 2016-2020

Table 50: China Biologics Market, 2016, By Segment

Table 51: China Biologics Percentage Of GDP, 2012-2020

Table 52: China Per Capita Average Biologics Expenditure, 2012-2020

Table 53: India Biologics Historic Market, 2012-2016

Table 54: India Biologics Forecast Market, 2016-2020

Table 55: India Biologics Market, 2016, By Segment

Table 56: India Biologics Percentage Of GDP, 2012-2020

Table 57: India Per Capita Average Biologics Expenditure, 2012-2020

Table 58: Japan Biologics Historic Market, 2012-2016

Table 59: Japan Biologics Forecast Market, 2016-2020

Table 60: Japan Biologics Market, 2016, By Segment

Table 61: Japan Biologics Percentage Of GDP, 2012-2020

Table 62: Japan Per Capita Average Biologics Expenditure, 2012-2020

Table 63: Japan Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 64: Japan Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 65: Australia Biologics Historic Market, 2012-2016

Table 66: Australia Biologics Forecast Market, 2016-2020

Table 67: Australia Biologics Market, 2016, By Segment

Table 68: Australia Biologics Percentage Of GDP, 2012-2020

Table 69: Australia Per Capita Average Biologics Expenditure, 2012-2020

Table 70: Western Europe Biologics Historic Market, 2012-2016

Table 71: Western Europe Biologics Forecast Market, 2016-2020

Table 72: Western Europe Biologics Market, 2016, By Segment

Table 73: UK Biologics Historic Market, 2012-2016

Table 74: UK Biologics Forecast Market, 2016-2020

Table 75: UK Biologics Market, 2016, By Segment

Table 76: UK Biologics Percentage Of GDP, 2012-2020

Table 77: UK Per Capita Average Biologics Expenditure, 2012-2020

Table 78: UK Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 79: UK Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 80: Germany Biologics Historic Market, 2012-2016

Table 81: Germany Biologics Forecast Market, 2016-2020

Table 82: Germany Biologics Market, 2016, By Segment

Table 83: Germany Biologics Percentage Of GDP, 2012-2020

Table 84: Germany Per Capita Average Biologics Expenditure, 2012-2020

Table 85: Germany Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 86: Germany Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 87: France Biologics Historic Market, 2012-2016

Table 88: France Biologics Forecast Market, 2016-2020

Table 89: France Biologics Market, 2016, By Segment

Table 90: France Biologics Percentage Of GDP, 2012-2020

Table 91: France Per Capita Average Biologics Expenditure, 2012-2020

Table 92: France Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 93: France Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 94: Italy Biologics Historic Market, 2012-2016

Table 95: Italy Biologics Forecast Market, 2016-2020

Table 96: Italy Biologics Market, 2016, By Segment

Table 97: Italy Biologics Percentage Of GDP, 2012-2020

Table 98: Italy Per Capita Average Biologics Expenditure, 2012-2020

Table 99: Italy Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 100: Italy Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 101: Spain Biologics Historic Market, 2012-2016

Table 102: Spain Biologics Forecast Market, 2016-2020

Table 103: Spain Biologics Market, 2016, By Segment

Table 104: Spain Biologics Percentage Of GDP, 2012-2020

Table 105: Spain Per Capita Average Biologics Expenditure, 2012-2020

Table 106: Spain Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 107: Spain Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 108: Eastern Europe Biologics Historic Market, 2012-2016

Table 109: Eastern Europe Biologics Forecast Market, 2016-2020

Table 110: Eastern Europe Biologics Market, 2016, By Segment

Table 111: Russia Biologics Historic Market, 2012-2016

Table 112: Russia Biologics Forecast Market, 2016-2020

Table 113: Russia Biologics Market, 2016, By Segment

Table 114: Russia Biologics Percentage Of GDP, 2012-2020

Table 115: Russia Per Capita Average Biologics Expenditure, 2012-2020

Table 116: North America Biologics Historic Market, 2012-2016

Table 117: North America Biologics Forecast Market, 2016-2020

Table 118: North America Biologics Market, 2016, By Segment

Table 119: USA Biologics Historic Market, 2012-2016

Table 120: USA Biologics Forecast Market, 2016-2020

Table 121: USA Biologics Market, 2016, By Segment

Table 122: USA Biologics Percentage Of GDP, 2012-2020

Table 123: USA Per Capita Average Biologics Expenditure, 2012-2020

Table 124: USA Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 125: USA Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 126: South America Biologics Historic Market, 2012-2016

Table 127: South America Biologics Forecast Market, 2016-2020

Table 128: South America Biologics Market, 2016, By Segment

Table 129: Brazil Biologics Historic Market, 2012-2016

Table 130: Brazil Biologics Forecast Market, 2016-2020

Table 131: Brazil Biologics Market, 2016, By Segment

Table 132: Brazil Biologics Percentage Of GDP, 2012-2020

Table 133: Brazil Per Capita Average Biologics Expenditure, 2012-2020

Table 134: Middle East Biologics Historic Market, 2012-2016

Table 135: Middle East Biologics Forecast Market, 2016-2020

Table 136: Middle East Biologics Market, 2016, By Segment

Table 137: Africa Biologics Historic Market, 2012-2016

Table 138: Africa Biologics Forecast Market, 2016-2020

Table 139: Africa Biologics Market, 2016, By Segment

Table 140: Johnson & Johnson Financial Performance

Table 141: Pfizer Inc. Financial Performance

Table 142: Novartis Ag Financial Performance

Table 143: Abbvie Financial Performance

Table 144: Sanofi Financial Performance

Table 145: Pharmaceutical Market Historic Growth

Table 146: Pharmaceutical Market Forecast Growth

Table 147: Global Pharmaceutical Market, 2016, By Region

Table 148: Global Pharmaceutical Market, 2012-2020, Historic And Forecast, By Region

Table 149: Pharmaceutical Market, 2016, By Country

Table 150: Pharmaceutical Market, 2012-2020, Historic And Forecast, By Country

Table 151: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Segment

Table 152: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Country And Segment;

Table 153: Pharmaceutical Market Size, Percentage Of GDP, Global

Table 154: Per Capita Average Pharmaceutical Expenditure, Global

Table 155: Pharmaceutical Market Comparison With Macro Economic Factors Across Countries

Table 156: Pharmaceutical Market Size, Percentage Of GDP, By Country

Table 157: Per Capita Average Pharmaceutical Expenditure, By Country

Table 158: Pharmaceuticals Industry Financial Margins


List Of Table

Figure 1: Global Biologics Historic Market Growth

Figure 2: Global Biologics Forecast Market Growth

Figure 3: Biologics Market Segmentation

Figure 4: Global Biologics Market, 2016, By Segment

Figure 5: Global Biologics Market, 2012-2020, Historic And Forecast, By Segment

Figure 6: Global Biologics Market Compared With Similar Markets, 2016

Figure 7: Global Biologics Market Compared With Similar Markets, 2012-2020, Historic and Forecast

Figure 8: Biologics Market Compared With Similar Markets, 2016, By Region

Figure 9: Biologics Market Compared With Similar Markets, 2016, By Country

Figure 10: Global Therapeutic Proteins Market, 2016, By Segment

Figure 11: Global Monoclonal Antibodies (MABS) Market, 2016, By Segment

Figure 12: Global Vaccines Market, 2016, By Segment

Figure 13: Global Biologics Market, 2016, By Region

Figure 14: Global Biologics Market, 2012-2020, Historic And Forecast, By Region

Figure 15: Biologics Market, 2016, By Country

Figure 16: Biologics Market, 2012-2020, Historic And Forecast, By Country

Figure 17: Global Healthcare Market Segments, 2016, By Region

Figure 18: Global Pharmaceuticals Market Segments, 2016, By Region

Figure 19: Global Healthcare Market Segments, 2016, By Country

Figure 20: Global Pharmaceuticals Market Segments, 2016, By Country;

Figure 21: Biologics Market Size, Percentage Of GDP, Global

Figure 22: Per Capita Average Biologics Expenditure, Global

Figure 23: Biologics Market Comparison With Macro Economic Factors Across Countries

Figure 24: Biologics Market Size, Percentage Of GDP, By Country

Figure 25: Per Capita Average Biologics Expenditure, By Country

Figure 26: Global Number Of Pharmacists, 2016, By Country

Figure 27: Global Biologics Market Revenue Versus Number Of Pharmacists, 2016, By Country

Figure 28: Global Number Of Pharma Enterprises, 2016, By Country

Figure 29: Global Biologics Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Figure 30: Global Number Of Employees In Pharmaceutical Industry, 2016, By Country

Figure 31: Global Biologics Market Revenue Versus Number Of Employees In Pharmaceutical Industry, 2016, By Country

Figure 32: Global Average Spending On R&D/Product Development, 2016, By Country

Figure 33: Global Biologics Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Figure 34: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 35: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 36: Global Generic & Branded Sales Proportion By Country (Volume), 2016, By Country

Figure 37: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2016, By Country

Figure 38: Global Number Of Pharmacies, 2016, By Country

Figure 39: Global Biologics Market Revenue Versus Number Of Pharmacies, 2016, By Country

Figure 40: Global New Drug Approvals, 2016, By Country

Figure 41: Global Biologics Market Revenue Versus New Drug Approvals, 2016, By Country

Figure 42: Prevalent Cases Of Thalassemia, 2014, By Country

Figure 43: Global Number Of General Practitioners 2016, By Country

Figure 44: Global Biologics Market Revenue Versus Number Of General Practitioners, 2016, By Country

Figure 45: Asia-Pacific Biologics Historic Market, 2012-2016

Figure 46: Asia-Pacific Biologics Forecast Market, 2016-2020

Figure 47: Asia-Pacific Biologics Market, 2016, By Segment

Figure 48: China Biologics Historic Market, 2012-2016

Figure 49: China Biologics Forecast Market, 2016-2020

Figure 50: China Biologics Market, 2016, By Segment

Figure 51: China Biologics Percentage Of GDP, 2012-2020

Figure 52: China Per Capita Average Biologics Expenditure, 2012-2020

Figure 53: India Biologics Historic Market, 2012-2016

Figure 54: India Biologics Forecast Market, 2016-2020

Figure 55: India Biologics Market, 2016, By Segment

Figure 56: India Biologics Percentage Of GDP, 2012-2020

Figure 57: India Per Capita Average Biologics Expenditure, 2012-2020

Figure 58: Japan Biologics Historic Market, 2012-2016

Figure 59: Japan Biologics Forecast Market, 2016-2020

Figure 60: Japan Biologics Market, 2016, By Segment

Figure 61: Japan Biologics Percentage Of GDP, 2012-2020

Figure 62: Japan Per Capita Average Biologics Expenditure, 2012-2020

Figure 63: Japan Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 64: Japan Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 65: Australia Biologics Historic Market, 2012-2016

Figure 66: Australia Biologics Forecast Market, 2016-2020

Figure 67: Australia Biologics Market, 2016, By Segment

Figure 68: Australia Biologics Percentage Of GDP, 2012-2020

Figure 69: Australia Per Capita Average Biologics Expenditure, 2012-2020

Figure 70: Western Europe Biologics Historic Market, 2012-2016

Figure 71: Western Europe Biologics Forecast Market, 2016-2020

Figure 72: Western Europe Biologics Market, 2016, By Segment

Figure 73: UK Biologics Historic Market, 2012-2016

Figure 74: UK Biologics Forecast Market, 2016-2020

Figure 75: UK Biologics Market, 2016, By Segment

Figure 76: UK Biologics Percentage Of GDP, 2012-2020

Figure 77: UK Per Capita Average Biologics Expenditure, 2012-2020

Figure 78: UK Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 79: UK Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 80: Germany Biologics Historic Market, 2012-2016

Figure 81: Germany Biologics Forecast Market, 2016-2020

Figure 82: Germany Biologics Market, 2016, By Segment

Figure 83: Germany Biologics Percentage Of GDP, 2012-2020

Figure 84: Germany Per Capita Average Biologics Expenditure, 2012-2020

Figure 85: Germany Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 86: Germany Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 87: France Biologics Historic Market, 2012-2016

Figure 88: France Biologics Forecast Market, 2016-2020

Figure 89: France Biologics Market, 2016, By Segment

Figure 90: France Biologics Percentage Of GDP, 2012-2020

Figure 91: France Per Capita Average Biologics Expenditure, 2012-2020

Figure 92: France Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 93: France Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 94: Italy Biologics Historic Market, 2012-2016

Figure 95: Italy Biologics Forecast Market, 2016-2020

Figure 96: Italy Biologics Market, 2016, By Segment

Figure 97: Italy Biologics Percentage Of GDP, 2012-2020

Figure 98: Italy Per Capita Average Biologics Expenditure, 2012-2020

Figure 99: Italy Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 100: Italy Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 101: Spain Biologics Historic Market, 2012-2016

Figure 102: Spain Biologics Forecast Market, 2016-2020

Figure 103: Spain Biologics Market, 2016, By Segment

Figure 104: Spain Biologics Percentage Of GDP, 2012-2020

Figure 105: Spain Per Capita Average Biologics Expenditure, 2012-2020

Figure 106: Spain Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 107: Spain Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 108: Eastern Europe Biologics Historic Market, 2012-2016

Figure 109: Eastern Europe Biologics Forecast Market, 2016-2020

Figure 110: Eastern Europe Biologics Market, 2016, By Segment

Figure 111: Russia Biologics Historic Market, 2012-2016

Figure 112: Russia Biologics Forecast Market, 2016-2020

Figure 113: Russia Biologics Market, 2016, By Segment

Figure 114: Russia Biologics Percentage Of GDP, 2012-2020

Figure 115: Russia Per Capita Average Biologics Expenditure, 2012-2020

Figure 116: North America Biologics Historic Market, 2012-2016

Figure 117: North America Biologics Forecast Market, 2016-2020

Figure 118: North America Biologics Market, 2016, By Segment

Figure 119: USA Biologics Historic Market, 2012-2016

Figure 120: USA Biologics Forecast Market, 2016-2020

Figure 121: USA Biologics Market, 2016, By Segment

Figure 122: USA Biologics Percentage Of GDP, 2012-2020

Figure 123: USA Per Capita Average Biologics Expenditure, 2012-2020

Figure 124: USA Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 125: USA Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 126: South America Biologics Historic Market, 2012-2016

Figure 127: South America Biologics Forecast Market, 2016-2020

Figure 128: South America Biologics Market, 2016, By Segment

Figure 129: Brazil Biologics Historic Market, 2012-2016

Figure 130: Brazil Biologics Forecast Market, 2016-2020

Figure 131: Brazil Biologics Market, 2016, By Segment

Figure 132: Brazil Biologics Percentage Of GDP, 2012-2020

Figure 133: Brazil Per Capita Average Biologics Expenditure, 2012-2020

Figure 134: Middle East Biologics Historic Market, 2012-2016

Figure 135: Middle East Biologics Forecast Market, 2016-2020

Figure 136: Middle East Biologics Market, 2016, By Segment

Figure 137: Africa Biologics Historic Market, 2012-2016

Figure 138: Africa Biologics Forecast Market, 2016-2020

Figure 139: Africa Biologics Market, 2016, By Segment

Figure 140: Johnson & Johnson Financial Performance

Figure 141: Pfizer Inc. Financial Performance

Figure 142: Novartis Ag Financial Performance

Figure 143: Abbvie Financial Performance

Figure 144: Sanofi Financial Performance

Figure 145: Pharmaceutical Market Historic Growth

Figure 146: Pharmaceutical Market Forecast Growth

Figure 147: Global Pharmaceutical Market, 2016, By Region

Figure 148: Global Pharmaceutical Market, 2012-2020, Historic And Forecast, By Region

Figure 149: Pharmaceutical Market, 2016, By Country

Figure 150: Pharmaceutical Market, 2012-2020, Historic And Forecast, By Country

Figure 151: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Segment

Figure 152: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Country And Segment;

Figure 153: Pharmaceutical Market Size, Percentage Of GDP, Global

Figure 154: Per Capita Average Pharmaceutical Expenditure, Global

Figure 155: Pharmaceutical Market Comparison With Macro Economic Factors Across Countries

Figure 156: Pharmaceutical Market Size, Percentage Of GDP, By Country

Figure 157: Per Capita Average Pharmaceutical Expenditure, By Country

Figure 158: Pharmaceuticals Industry Financial Margins

Licence Rights

  • Single User License (for access by one person)
  • Site License (for access of one office location of a company)
  • Corporate License (allow access by all staff of the company)

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Therapeutic Proteins, Monoclonal Antibodies (MABS), Vaccines


Companies

Johnson & Johnson, Pfizer Inc., Novartis AG, Abbvie, and Sanofi

Company Profile

Company Profile Title

Biologics market covers biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnology methods and other cutting-edge technologies.

The global biologics market was estimated to be around $210 billion as of 2016. It made up around 20% of the overall pharmaceuticals market in 2016. The biologics was the second largest market, following the pharmaceutical drugs market in the global pharmaceutical market in 2016.

Treatment of complex diseases

Biologics provide effective treatment for many complex diseases such as Rheumatoid arthritis that have less treatment options. There has been significant advancement for the treatment of Rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of Rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan).

The Biologics Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global satellite and telecommunications resellers sector.

Reasons to Purchase

Outperform competitors using accurate up to date demand-side dynamics information.

Identify growth segments for investment.

Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.

Create regional and country strategies on the basis of local data and analysis.

Stay abreast of the latest customer and market research findings

Benchmark performance against key competitors.

Develop strategies based on likely future developments.

Utilize the relationships between key data sets for superior strategizing.

Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Gain a global perspective on the development of the market.

Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:

Where is the largest and fastest growing market for the biologics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical market, and compares it with other markets.

The market characteristics section of the report defines and explains the market.

The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down market into sub markets.

The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.

The biologics market section of the report gives context. It compares the biologics market with other segments of the pharmaceutical market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The biologics Indicators Comparison.

The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.

Scope

Markets Covered: Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines

Companies Mentioned: Johnson & Johnson, Pfizer Inc., Novartis AG, Abbvie, and Sanofi

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Biologics Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

READ MORE

Scope

1. Biologics Market Characteristics;

2. Biologics Market Size And Growth;

2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;

3. Pestle Analysis;

3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;

4. Biologics Market Customer Information;

5. Biologics Market Segmentation;

5.1. Global Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 5.2. Global Biologics Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Biologics Market Trends And Strategies; 5.4 Global Biologics Market Compared With Similar Markets, 2016; 5.5 Global Biologics Market Compared With Similar Markets, 2012-2020, Historic and Forecast; 5.6 Biologics Market Compared With Similar Markets, 2016, By Region; 5.7 Biologics Market Compared With Similar Markets, 2016, By Country; 5.8 Therapeutic Proteins; 5.8.1. Market Characteristics; 5.8.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment; 5.8.3. Market Trends And Strategies; 5.9 Monoclonal Antibodies (MABS); 5.9.1. Market Characteristics; 5.9.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment; 5.9.3. Market Trends And Strategies; 5.10 Vaccines; 5.9.1. Market Characteristics; 5.10.2. Global Internet Broadcasting & Publishing Market, 2016, By Segment; 5.10.3. Market Trends And Strategies;

6. Biologics Market Regional And Country Analysis;

6.1. Global Biologics Market, 2016, By Region; 6.2. Global Biologics Market, 2012-2020, Historic And Forecast, By Region; 6.3. Biologics Market, 2016, By Country; 6.4. Biologics Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Healthcare Market Segments, 2016, By Region; 6.6. Global Pharmaceuticals Market Segments, 2016, By Region; 6.7. Global Healthcare Market Segments, 2016, By Country; 6.8. Global Pharmaceuticals Market Segments, 2016, By Country;

7. Global Biologics Market Comparison With Macro Economic Factors;

7.1. Biologics Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Biologics Expenditure, Global;

8. Biologics Market Comparison With Macro Economic Factors Across Countries;

8.1. Biologics Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Biologics Expenditure, By Country;

9. Biologics Market Comparison With Industry Metrics;

9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Biologics Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Biologics Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Number Of Employees In Pharmaceutical Industry, 2016, By Country; 9.6. Global Biologics Market Revenue Versus Number Of Employees In Pharmaceutical Industry, 2016, By Country; 9.7. Global Average Spending On R&D/Product Development, 2016, By Country; 9.8. Global Biologics Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.9. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.10. Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.11. Global Generic & Branded Sales Proportion By Country (Volume), 2016, By Country; 9.12. Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2016, By Country; 9.13. Global Number Of Pharmacies, 2016, By Country; 9.14. Global Biologics Market Revenue Versus Number Of Pharmacies, 2016, By Country; 9.15. Global New Drug Approvals, 2016, By Country; 9.16. Global Biologics Market Revenue Versus New Drug Approvals, 2016, By Country; 9.17. Prevalent Cases Of Thalassemia, 2014, By Country; 9.18. Global Number Of General Practitioners 2016, By Country; 9.19. Global Biologics Market Revenue Versus Number Of General Practitioners, 2016, By Country;

10. Asia-Pacific Biologics Market;

10.1.1. Asia-Pacific Biologics Market Overview; 10.1.2. Asia-Pacific Biologics Historic Market, 2012-2016; 10.1.3. Asia-Pacific Biologics Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.2. Asia-Pacific Biologics Market: Country Analysis; 10.3. China Biologics Market; 10.3.1. China Biologics Market Overview; Average Salaries Of Pharmacists; 10.3.2. China Biologics Historic Market, 2012-2016; 10.3.3. China Biologics Forecast Market, 2016-2020; 10.3.4. China Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.3.5. China Biologics Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Biologics Expenditure, 2012-2020; 10.4. India Biologics Market; 10.4.1. India Biologics Market Overview; Average Salaries Of Pharmacists; 10.4.2. India Biologics Historic Market, 2012-2016; 10.4.3. India Biologics Forecast Market, 2016-2020; 10.4.4. India Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.4.5. India Biologics Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Biologics Expenditure, 2012-2020; 10.5. Japan Biologics Market; 10.5.1. Japan Biologics Market Overview; Average Salaries Of Pharmacists; 10.5.2. Japan Biologics Historic Market, 2012-2016; 10.5.3. Japan Biologics Forecast Market, 2016-2020; 10.5.4. Japan Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.5.5. Japan Biologics Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Biologics Expenditure, 2012-2020; 10.5.7. Japan Biologics Market Comparison With Industry Metrics; 10.5.7.1. Japan Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 10.5.7.2. Japan Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 10.6. Australia Biologics Market; 10.6.1. Australia Biologics Historic Market, 2012-2016; 10.6.2. Australia Biologics Forecast Market, 2016-2020; 10.6.3. Australia Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 10.6.4. Australia Biologics Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Biologics Expenditure, 2012-2020;

11. Western Europe Biologics Market;

11.1.1. Western Europe Biologics Market Overview; 11.1.2. Western Europe Biologics Historic Market, 2012-2016; 11.1.3. Western Europe Biologics Forecast Market, 2016-2020; 11.1.4. Western Europe Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.2. Western Europe Biologics Market: Country Analysis; 11.3. UK Biologics Market; 11.3.1. UK Biologics Market Overview; Average Salaries Of Pharmacists; 11.3.2. UK Biologics Historic Market, 2012-2016; 11.3.3. UK Biologics Forecast Market, 2016-2020; 11.3.4. UK Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.3.5. UK Biologics Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Biologics Expenditure, 2012-2020; 11.3.7. UK Biologics Market Comparison With Industry Metrics; 11.3.7.1 UK Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.3.7.2 UK Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.4. Germany Biologics Market; 11.4.1. Germany Biologics Historic Market, 2012-2016; 11.4.2. Germany Biologics Forecast Market, 2016-2020; 11.4.3. Germany Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.4.4 Germany Biologics Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Biologics Expenditure, 2012-2020; 11.4.6 Germany Biologics Market Comparison With Industry Metrics; 11.4.7.1 Germany Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.4.7.2 Germany Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.5 France Biologics Market; 11.5.1 France Biologics Historic Market, 2012-2016; 11.5.2 France Biologics Forecast Market, 2016-2020; 11.5.3 France Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.5.4 France Biologics Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Biologics Expenditure, 2012-2020; 11.5.6 France Biologics Market Comparison With Industry Metrics; 11.5.6.1 France Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.5.6.2 France Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.6. Italy Biologics Market; 11.6.1. Italy Biologics Historic Market, 2012-2016; 11.6.2. Italy Biologics Forecast Market, 2016-2020; 11.6.3. Italy Biologics Market, 2016, By Segment; Therapeutic Proteins; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.6.4. Italy Biologics Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Biologics Expenditure, 2012-2020; 11.6.6. Italy Biologics Market Comparison With Industry Metrics; 11.6.6.1 Italy Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.6.6.2 Italy Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.7. Spain Biologics Market; 11.7.1. Spain Biologics Historic Market, 2012-2016; 11.7.2. Spain Biologics Forecast Market, 2016-2020; 11.7.3. Spain Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 11.7.4. Spain Biologics Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Biologics Expenditure, 2012-2020; 11.7.6. Spain Biologics Market Comparison With Industry Metrics; 11.7.6.1 Spain Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 11.7.6.2 Spain Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016;

12. Eastern Europe Biologics Market;

12.1.1. Eastern Europe Biologics Market Overview; 12.1.2. Eastern Europe Biologics Historic Market, 2012-2016; 12.1.3. Eastern Europe Biologics Forecast Market, 2016-2020; 12.1.4 Eastern Europe Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 12.2. Eastern Europe Biologics Market: Country Analysis; 12.3. Russia Biologics Market; 12.3.1. Russia Biologics Historic Market, 2012-2016; 12.3.2. Russia Biologics Forecast Market, 2016-2020; 12.3.3. Russia Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 12.3.4. Russia Biologics Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Biologics Expenditure, 2012-2020;

13. North America Biologics Market;

13.1.1. North America Biologics Market Overview; 13.1.2. North America Biologics Historic Market, 2012-2016; 13.1.3. North America Biologics Forecast Market, 2016-2020; 13.1.4. North America Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 13.2. North America Biologics Market: Country Analysis; 13.3. USA Biologics Market; 13.3.1. USA Biologics Historic Market, 2012-2016; 13.3.2. USA Biologics Forecast Market, 2016-2020; 13.3.3 USA Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 13.3.4. USA Biologics Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Biologics Expenditure, 2012-2020; 13.3.6. USA Biologics Market Comparison With Industry Metrics; 13.3.6.1 USA Generic & Branded Sales Proportion By Country (Volume), 2012-2016; 13.3.6.2 USA Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016;

14. South America Biologics Market;

14.1.1. South America Biologics Market Overview; 14.1.2. South America Biologics Historic Market, 2012-2016; 14.1.3. South America Biologics Forecast Market, 2016-2020; 14.1.4. South America Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 14.2. South America Biologics Market: Country Analysis; 14.3. Brazil Biologics Market; 14.3.1. Brazil Biologics Historic Market, 2012-2016; 14.3.2. Brazil Biologics Forecast Market, 2016-2020; 14.3.3. Brazil Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines; 14.3.4. Brazil Biologics Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Biologics Expenditure, 2012-2020;

15. Middle East Biologics Market;

15.1.1. Middle East Biologics Market Overview; 15.1.2. Middle East Biologics Historic Market, 2012-2016; 15.1.3. Middle East Biologics Forecast Market, 2016-2020; 15.1.4. Middle East Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines;

16.1.1. Africa Biologics Market Overview; 16.1.2. Africa Biologics Historic Market, 2012-2016; 16.1.3. Africa Biologics Forecast Market, 2016-2020; 16.1.4. Africa Biologics Market, 2016, By Segment; Therapeutic Proteins; Monoclonal Antibodies (MABS); Vaccines;

17. Biologics Market Competitive Landscape;

17.1. Company Profiles; 17.2. Johnson & Johnson; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Pfizer Inc.; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Novartis Ag; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Abbvie; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Sanofi; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;

18. Key Mergers And Acquisitions In The Biologics Market;

19. Market Background: Pharmaceuticals Market;

19.1.1. Pharmaceutical Market Characteristics; 19.1.2. Pharmaceutical Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Trends And Strategies; 19.2. Pharmaceutical Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Market, 2016, By Region; 19.2.2. Global Pharmaceutical Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Market, 2016, By Country; 19.2.4. Pharmaceutical Market, 2012-2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceuticals Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceuticals Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceuticals Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Expenditure, Global; 19.4. Pharmaceutical Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Market;

20. Pharmaceuticals Industry Financial Margins;

21. Appendix;

21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer


List Of Figure

Table 1: Global Biologics Historic Market Growth

Table 2: Global Biologics Forecast Market Growth

Table 3: Biologics Market Segmentation

Table 4: Global Biologics Market, 2016, By Segment

Table 5: Global Biologics Market, 2012-2020, Historic And Forecast, By Segment

Table 6: Global Biologics Market Compared With Similar Markets, 2016

Table 7: Global Biologics Market Compared With Similar Markets, 2012-2020, Historic and Forecast

Table 8: Biologics Market Compared With Similar Markets, 2016, By Region

Table 9: Biologics Market Compared With Similar Markets, 2016, By Country

Table 10: Global Therapeutic Proteins Market, 2016, By Segment

Table 11: Global Monoclonal Antibodies (MABS) Market, 2016, By Segment

Table 12: Global Vaccines Market, 2016, By Segment

Table 13: Global Biologics Market, 2016, By Region

Table 14: Global Biologics Market, 2012-2020, Historic And Forecast, By Region

Table 15: Biologics Market, 2016, By Country

Table 16: Biologics Market, 2012-2020, Historic And Forecast, By Country

Table 17: Global Healthcare Market Segments, 2016, By Region

Table 18: Global Pharmaceuticals Market Segments, 2016, By Region

Table 19: Global Healthcare Market Segments, 2016, By Country

Table 20: Global Pharmaceuticals Market Segments, 2016, By Country;

Table 21: Biologics Market Size, Percentage Of GDP, Global

Table 22: Per Capita Average Biologics Expenditure, Global

Table 23: Biologics Market Comparison With Macro Economic Factors Across Countries

Table 24: Biologics Market Size, Percentage Of GDP, By Country

Table 25: Per Capita Average Biologics Expenditure, By Country

Table 26: Global Number Of Pharmacists, 2016, By Country

Table 27: Global Biologics Market Revenue Versus Number Of Pharmacists, 2016, By Country

Table 28: Global Number Of Pharma Enterprises, 2016, By Country

Table 29: Global Biologics Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Table 30: Global Number Of Employees In Pharmaceutical Industry, 2016, By Country

Table 31: Global Biologics Market Revenue Versus Number Of Employees In Pharmaceutical Industry, 2016, By Country

Table 32: Global Average Spending On R&D/Product Development, 2016, By Country

Table 33: Global Biologics Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Table 34: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 35: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 36: Global Generic & Branded Sales Proportion By Country (Volume), 2016, By Country

Table 37: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2016, By Country

Table 38: Global Number Of Pharmacies, 2016, By Country

Table 39: Global Biologics Market Revenue Versus Number Of Pharmacies, 2016, By Country

Table 40: Global New Drug Approvals, 2016, By Country

Table 41: Global Biologics Market Revenue Versus New Drug Approvals, 2016, By Country

Table 42: Prevalent Cases Of Thalassemia, 2014, By Country

Table 43: Global Number Of General Practitioners 2016, By Country

Table 44: Global Biologics Market Revenue Versus Number Of General Practitioners, 2016, By Country

Table 45: Asia-Pacific Biologics Historic Market, 2012-2016

Table 46: Asia-Pacific Biologics Forecast Market, 2016-2020

Table 47: Asia-Pacific Biologics Market, 2016, By Segment

Table 48: China Biologics Historic Market, 2012-2016

Table 49: China Biologics Forecast Market, 2016-2020

Table 50: China Biologics Market, 2016, By Segment

Table 51: China Biologics Percentage Of GDP, 2012-2020

Table 52: China Per Capita Average Biologics Expenditure, 2012-2020

Table 53: India Biologics Historic Market, 2012-2016

Table 54: India Biologics Forecast Market, 2016-2020

Table 55: India Biologics Market, 2016, By Segment

Table 56: India Biologics Percentage Of GDP, 2012-2020

Table 57: India Per Capita Average Biologics Expenditure, 2012-2020

Table 58: Japan Biologics Historic Market, 2012-2016

Table 59: Japan Biologics Forecast Market, 2016-2020

Table 60: Japan Biologics Market, 2016, By Segment

Table 61: Japan Biologics Percentage Of GDP, 2012-2020

Table 62: Japan Per Capita Average Biologics Expenditure, 2012-2020

Table 63: Japan Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 64: Japan Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 65: Australia Biologics Historic Market, 2012-2016

Table 66: Australia Biologics Forecast Market, 2016-2020

Table 67: Australia Biologics Market, 2016, By Segment

Table 68: Australia Biologics Percentage Of GDP, 2012-2020

Table 69: Australia Per Capita Average Biologics Expenditure, 2012-2020

Table 70: Western Europe Biologics Historic Market, 2012-2016

Table 71: Western Europe Biologics Forecast Market, 2016-2020

Table 72: Western Europe Biologics Market, 2016, By Segment

Table 73: UK Biologics Historic Market, 2012-2016

Table 74: UK Biologics Forecast Market, 2016-2020

Table 75: UK Biologics Market, 2016, By Segment

Table 76: UK Biologics Percentage Of GDP, 2012-2020

Table 77: UK Per Capita Average Biologics Expenditure, 2012-2020

Table 78: UK Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 79: UK Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 80: Germany Biologics Historic Market, 2012-2016

Table 81: Germany Biologics Forecast Market, 2016-2020

Table 82: Germany Biologics Market, 2016, By Segment

Table 83: Germany Biologics Percentage Of GDP, 2012-2020

Table 84: Germany Per Capita Average Biologics Expenditure, 2012-2020

Table 85: Germany Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 86: Germany Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 87: France Biologics Historic Market, 2012-2016

Table 88: France Biologics Forecast Market, 2016-2020

Table 89: France Biologics Market, 2016, By Segment

Table 90: France Biologics Percentage Of GDP, 2012-2020

Table 91: France Per Capita Average Biologics Expenditure, 2012-2020

Table 92: France Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 93: France Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 94: Italy Biologics Historic Market, 2012-2016

Table 95: Italy Biologics Forecast Market, 2016-2020

Table 96: Italy Biologics Market, 2016, By Segment

Table 97: Italy Biologics Percentage Of GDP, 2012-2020

Table 98: Italy Per Capita Average Biologics Expenditure, 2012-2020

Table 99: Italy Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 100: Italy Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 101: Spain Biologics Historic Market, 2012-2016

Table 102: Spain Biologics Forecast Market, 2016-2020

Table 103: Spain Biologics Market, 2016, By Segment

Table 104: Spain Biologics Percentage Of GDP, 2012-2020

Table 105: Spain Per Capita Average Biologics Expenditure, 2012-2020

Table 106: Spain Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 107: Spain Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 108: Eastern Europe Biologics Historic Market, 2012-2016

Table 109: Eastern Europe Biologics Forecast Market, 2016-2020

Table 110: Eastern Europe Biologics Market, 2016, By Segment

Table 111: Russia Biologics Historic Market, 2012-2016

Table 112: Russia Biologics Forecast Market, 2016-2020

Table 113: Russia Biologics Market, 2016, By Segment

Table 114: Russia Biologics Percentage Of GDP, 2012-2020

Table 115: Russia Per Capita Average Biologics Expenditure, 2012-2020

Table 116: North America Biologics Historic Market, 2012-2016

Table 117: North America Biologics Forecast Market, 2016-2020

Table 118: North America Biologics Market, 2016, By Segment

Table 119: USA Biologics Historic Market, 2012-2016

Table 120: USA Biologics Forecast Market, 2016-2020

Table 121: USA Biologics Market, 2016, By Segment

Table 122: USA Biologics Percentage Of GDP, 2012-2020

Table 123: USA Per Capita Average Biologics Expenditure, 2012-2020

Table 124: USA Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 125: USA Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Table 126: South America Biologics Historic Market, 2012-2016

Table 127: South America Biologics Forecast Market, 2016-2020

Table 128: South America Biologics Market, 2016, By Segment

Table 129: Brazil Biologics Historic Market, 2012-2016

Table 130: Brazil Biologics Forecast Market, 2016-2020

Table 131: Brazil Biologics Market, 2016, By Segment

Table 132: Brazil Biologics Percentage Of GDP, 2012-2020

Table 133: Brazil Per Capita Average Biologics Expenditure, 2012-2020

Table 134: Middle East Biologics Historic Market, 2012-2016

Table 135: Middle East Biologics Forecast Market, 2016-2020

Table 136: Middle East Biologics Market, 2016, By Segment

Table 137: Africa Biologics Historic Market, 2012-2016

Table 138: Africa Biologics Forecast Market, 2016-2020

Table 139: Africa Biologics Market, 2016, By Segment

Table 140: Johnson & Johnson Financial Performance

Table 141: Pfizer Inc. Financial Performance

Table 142: Novartis Ag Financial Performance

Table 143: Abbvie Financial Performance

Table 144: Sanofi Financial Performance

Table 145: Pharmaceutical Market Historic Growth

Table 146: Pharmaceutical Market Forecast Growth

Table 147: Global Pharmaceutical Market, 2016, By Region

Table 148: Global Pharmaceutical Market, 2012-2020, Historic And Forecast, By Region

Table 149: Pharmaceutical Market, 2016, By Country

Table 150: Pharmaceutical Market, 2012-2020, Historic And Forecast, By Country

Table 151: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Segment

Table 152: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Country And Segment;

Table 153: Pharmaceutical Market Size, Percentage Of GDP, Global

Table 154: Per Capita Average Pharmaceutical Expenditure, Global

Table 155: Pharmaceutical Market Comparison With Macro Economic Factors Across Countries

Table 156: Pharmaceutical Market Size, Percentage Of GDP, By Country

Table 157: Per Capita Average Pharmaceutical Expenditure, By Country

Table 158: Pharmaceuticals Industry Financial Margins


List Of Table

Figure 1: Global Biologics Historic Market Growth

Figure 2: Global Biologics Forecast Market Growth

Figure 3: Biologics Market Segmentation

Figure 4: Global Biologics Market, 2016, By Segment

Figure 5: Global Biologics Market, 2012-2020, Historic And Forecast, By Segment

Figure 6: Global Biologics Market Compared With Similar Markets, 2016

Figure 7: Global Biologics Market Compared With Similar Markets, 2012-2020, Historic and Forecast

Figure 8: Biologics Market Compared With Similar Markets, 2016, By Region

Figure 9: Biologics Market Compared With Similar Markets, 2016, By Country

Figure 10: Global Therapeutic Proteins Market, 2016, By Segment

Figure 11: Global Monoclonal Antibodies (MABS) Market, 2016, By Segment

Figure 12: Global Vaccines Market, 2016, By Segment

Figure 13: Global Biologics Market, 2016, By Region

Figure 14: Global Biologics Market, 2012-2020, Historic And Forecast, By Region

Figure 15: Biologics Market, 2016, By Country

Figure 16: Biologics Market, 2012-2020, Historic And Forecast, By Country

Figure 17: Global Healthcare Market Segments, 2016, By Region

Figure 18: Global Pharmaceuticals Market Segments, 2016, By Region

Figure 19: Global Healthcare Market Segments, 2016, By Country

Figure 20: Global Pharmaceuticals Market Segments, 2016, By Country;

Figure 21: Biologics Market Size, Percentage Of GDP, Global

Figure 22: Per Capita Average Biologics Expenditure, Global

Figure 23: Biologics Market Comparison With Macro Economic Factors Across Countries

Figure 24: Biologics Market Size, Percentage Of GDP, By Country

Figure 25: Per Capita Average Biologics Expenditure, By Country

Figure 26: Global Number Of Pharmacists, 2016, By Country

Figure 27: Global Biologics Market Revenue Versus Number Of Pharmacists, 2016, By Country

Figure 28: Global Number Of Pharma Enterprises, 2016, By Country

Figure 29: Global Biologics Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Figure 30: Global Number Of Employees In Pharmaceutical Industry, 2016, By Country

Figure 31: Global Biologics Market Revenue Versus Number Of Employees In Pharmaceutical Industry, 2016, By Country

Figure 32: Global Average Spending On R&D/Product Development, 2016, By Country

Figure 33: Global Biologics Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Figure 34: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 35: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 36: Global Generic & Branded Sales Proportion By Country (Volume), 2016, By Country

Figure 37: Global Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2016, By Country

Figure 38: Global Number Of Pharmacies, 2016, By Country

Figure 39: Global Biologics Market Revenue Versus Number Of Pharmacies, 2016, By Country

Figure 40: Global New Drug Approvals, 2016, By Country

Figure 41: Global Biologics Market Revenue Versus New Drug Approvals, 2016, By Country

Figure 42: Prevalent Cases Of Thalassemia, 2014, By Country

Figure 43: Global Number Of General Practitioners 2016, By Country

Figure 44: Global Biologics Market Revenue Versus Number Of General Practitioners, 2016, By Country

Figure 45: Asia-Pacific Biologics Historic Market, 2012-2016

Figure 46: Asia-Pacific Biologics Forecast Market, 2016-2020

Figure 47: Asia-Pacific Biologics Market, 2016, By Segment

Figure 48: China Biologics Historic Market, 2012-2016

Figure 49: China Biologics Forecast Market, 2016-2020

Figure 50: China Biologics Market, 2016, By Segment

Figure 51: China Biologics Percentage Of GDP, 2012-2020

Figure 52: China Per Capita Average Biologics Expenditure, 2012-2020

Figure 53: India Biologics Historic Market, 2012-2016

Figure 54: India Biologics Forecast Market, 2016-2020

Figure 55: India Biologics Market, 2016, By Segment

Figure 56: India Biologics Percentage Of GDP, 2012-2020

Figure 57: India Per Capita Average Biologics Expenditure, 2012-2020

Figure 58: Japan Biologics Historic Market, 2012-2016

Figure 59: Japan Biologics Forecast Market, 2016-2020

Figure 60: Japan Biologics Market, 2016, By Segment

Figure 61: Japan Biologics Percentage Of GDP, 2012-2020

Figure 62: Japan Per Capita Average Biologics Expenditure, 2012-2020

Figure 63: Japan Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 64: Japan Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 65: Australia Biologics Historic Market, 2012-2016

Figure 66: Australia Biologics Forecast Market, 2016-2020

Figure 67: Australia Biologics Market, 2016, By Segment

Figure 68: Australia Biologics Percentage Of GDP, 2012-2020

Figure 69: Australia Per Capita Average Biologics Expenditure, 2012-2020

Figure 70: Western Europe Biologics Historic Market, 2012-2016

Figure 71: Western Europe Biologics Forecast Market, 2016-2020

Figure 72: Western Europe Biologics Market, 2016, By Segment

Figure 73: UK Biologics Historic Market, 2012-2016

Figure 74: UK Biologics Forecast Market, 2016-2020

Figure 75: UK Biologics Market, 2016, By Segment

Figure 76: UK Biologics Percentage Of GDP, 2012-2020

Figure 77: UK Per Capita Average Biologics Expenditure, 2012-2020

Figure 78: UK Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 79: UK Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 80: Germany Biologics Historic Market, 2012-2016

Figure 81: Germany Biologics Forecast Market, 2016-2020

Figure 82: Germany Biologics Market, 2016, By Segment

Figure 83: Germany Biologics Percentage Of GDP, 2012-2020

Figure 84: Germany Per Capita Average Biologics Expenditure, 2012-2020

Figure 85: Germany Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 86: Germany Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 87: France Biologics Historic Market, 2012-2016

Figure 88: France Biologics Forecast Market, 2016-2020

Figure 89: France Biologics Market, 2016, By Segment

Figure 90: France Biologics Percentage Of GDP, 2012-2020

Figure 91: France Per Capita Average Biologics Expenditure, 2012-2020

Figure 92: France Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 93: France Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 94: Italy Biologics Historic Market, 2012-2016

Figure 95: Italy Biologics Forecast Market, 2016-2020

Figure 96: Italy Biologics Market, 2016, By Segment

Figure 97: Italy Biologics Percentage Of GDP, 2012-2020

Figure 98: Italy Per Capita Average Biologics Expenditure, 2012-2020

Figure 99: Italy Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 100: Italy Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 101: Spain Biologics Historic Market, 2012-2016

Figure 102: Spain Biologics Forecast Market, 2016-2020

Figure 103: Spain Biologics Market, 2016, By Segment

Figure 104: Spain Biologics Percentage Of GDP, 2012-2020

Figure 105: Spain Per Capita Average Biologics Expenditure, 2012-2020

Figure 106: Spain Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 107: Spain Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 108: Eastern Europe Biologics Historic Market, 2012-2016

Figure 109: Eastern Europe Biologics Forecast Market, 2016-2020

Figure 110: Eastern Europe Biologics Market, 2016, By Segment

Figure 111: Russia Biologics Historic Market, 2012-2016

Figure 112: Russia Biologics Forecast Market, 2016-2020

Figure 113: Russia Biologics Market, 2016, By Segment

Figure 114: Russia Biologics Percentage Of GDP, 2012-2020

Figure 115: Russia Per Capita Average Biologics Expenditure, 2012-2020

Figure 116: North America Biologics Historic Market, 2012-2016

Figure 117: North America Biologics Forecast Market, 2016-2020

Figure 118: North America Biologics Market, 2016, By Segment

Figure 119: USA Biologics Historic Market, 2012-2016

Figure 120: USA Biologics Forecast Market, 2016-2020

Figure 121: USA Biologics Market, 2016, By Segment

Figure 122: USA Biologics Percentage Of GDP, 2012-2020

Figure 123: USA Per Capita Average Biologics Expenditure, 2012-2020

Figure 124: USA Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 125: USA Biologics Market Revenue Versus Generic & Branded Sales Proportion By Country (Volume), 2012-2016

Figure 126: South America Biologics Historic Market, 2012-2016

Figure 127: South America Biologics Forecast Market, 2016-2020

Figure 128: South America Biologics Market, 2016, By Segment

Figure 129: Brazil Biologics Historic Market, 2012-2016

Figure 130: Brazil Biologics Forecast Market, 2016-2020

Figure 131: Brazil Biologics Market, 2016, By Segment

Figure 132: Brazil Biologics Percentage Of GDP, 2012-2020

Figure 133: Brazil Per Capita Average Biologics Expenditure, 2012-2020

Figure 134: Middle East Biologics Historic Market, 2012-2016

Figure 135: Middle East Biologics Forecast Market, 2016-2020

Figure 136: Middle East Biologics Market, 2016, By Segment

Figure 137: Africa Biologics Historic Market, 2012-2016

Figure 138: Africa Biologics Forecast Market, 2016-2020

Figure 139: Africa Biologics Market, 2016, By Segment

Figure 140: Johnson & Johnson Financial Performance

Figure 141: Pfizer Inc. Financial Performance

Figure 142: Novartis Ag Financial Performance

Figure 143: Abbvie Financial Performance

Figure 144: Sanofi Financial Performance

Figure 145: Pharmaceutical Market Historic Growth

Figure 146: Pharmaceutical Market Forecast Growth

Figure 147: Global Pharmaceutical Market, 2016, By Region

Figure 148: Global Pharmaceutical Market, 2012-2020, Historic And Forecast, By Region

Figure 149: Pharmaceutical Market, 2016, By Country

Figure 150: Pharmaceutical Market, 2012-2020, Historic And Forecast, By Country

Figure 151: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Segment

Figure 152: Global Pharmaceuticals Market, Growth And Market Share Comparison, By Country And Segment;

Figure 153: Pharmaceutical Market Size, Percentage Of GDP, Global

Figure 154: Per Capita Average Pharmaceutical Expenditure, Global

Figure 155: Pharmaceutical Market Comparison With Macro Economic Factors Across Countries

Figure 156: Pharmaceutical Market Size, Percentage Of GDP, By Country

Figure 157: Per Capita Average Pharmaceutical Expenditure, By Country

Figure 158: Pharmaceuticals Industry Financial Margins

  • Single User License (for access by one person)
  • Site License (for access of one office location of a company)
  • Corporate License (allow access by all staff of the company)
To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Therapeutic Proteins, Monoclonal Antibodies (MABS), Vaccines


Companies

Johnson & Johnson, Pfizer Inc., Novartis AG, Abbvie, and Sanofi